DE19940740A1 - Pharmazeutische Salze - Google Patents

Pharmazeutische Salze

Info

Publication number
DE19940740A1
DE19940740A1 DE19940740A DE19940740A DE19940740A1 DE 19940740 A1 DE19940740 A1 DE 19940740A1 DE 19940740 A DE19940740 A DE 19940740A DE 19940740 A DE19940740 A DE 19940740A DE 19940740 A1 DE19940740 A1 DE 19940740A1
Authority
DE
Germany
Prior art keywords
tramadol
medicament
manufacture
treatment
salt according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19940740A
Other languages
German (de)
English (en)
Inventor
Heinrich Kugelmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to DE19940740A priority Critical patent/DE19940740A1/de
Priority to IL14841100A priority patent/IL148411A0/xx
Priority to RU2002106741/15A priority patent/RU2292877C2/ru
Priority to HU0203623A priority patent/HUP0203623A2/hu
Priority to JP2001519896A priority patent/JP2003508429A/ja
Priority to JP2001519897A priority patent/JP2003508430A/ja
Priority to MXPA02002193A priority patent/MXPA02002193A/es
Priority to HK02108598.7A priority patent/HK1047229B/zh
Priority to HK02108599.6A priority patent/HK1047230B/zh
Priority to NZ517366A priority patent/NZ517366A/en
Priority to PCT/EP2000/007527 priority patent/WO2001015683A1/de
Priority to PL00354264A priority patent/PL354264A1/xx
Priority to AT00949447T priority patent/ATE279186T1/de
Priority to ES00958375T priority patent/ES2284523T3/es
Priority to DE2000508261 priority patent/DE50008261D1/de
Priority to BR0015048-7A priority patent/BR0015048A/pt
Priority to AT00958375T priority patent/ATE359064T1/de
Priority to ES00949447T priority patent/ES2226886T3/es
Priority to IL14840600A priority patent/IL148406A0/xx
Priority to CNB008150931A priority patent/CN1202815C/zh
Priority to CA002388560A priority patent/CA2388560A1/en
Priority to MXPA02002024A priority patent/MXPA02002024A/es
Priority to BR0013825-8A priority patent/BR0013825A/pt
Priority to SK276-2002A priority patent/SK2762002A3/sk
Priority to SK235-2002A priority patent/SK285987B6/sk
Priority to KR1020027002625A priority patent/KR20020031419A/ko
Priority to AU62798/00A priority patent/AU781058B2/en
Priority to DK00958375T priority patent/DK1207868T3/da
Priority to RU2002106748/15A priority patent/RU2292876C2/ru
Priority to KR1020027002634A priority patent/KR100730502B1/ko
Priority to EP00949447A priority patent/EP1207866B1/de
Priority to CA002386690A priority patent/CA2386690C/en
Priority to SI200030952T priority patent/SI1207868T1/sl
Priority to SI200030515T priority patent/SI1207866T1/xx
Priority to MYPI20003557A priority patent/MY127683A/en
Priority to HU0302131A priority patent/HUP0302131A2/hu
Priority to PCT/EP2000/007526 priority patent/WO2001015682A1/de
Priority to NZ517559A priority patent/NZ517559A/en
Priority to PT00958375T priority patent/PT1207868E/pt
Priority to CNB008121591A priority patent/CN1200700C/zh
Priority to PL354238A priority patent/PL212105B1/pl
Priority to AU69921/00A priority patent/AU781852B2/en
Priority to DE50014244T priority patent/DE50014244D1/de
Priority to CZ2002671A priority patent/CZ2002671A3/cs
Priority to CZ20020674A priority patent/CZ301259B6/cs
Priority to PT00949447T priority patent/PT1207866E/pt
Priority to EP00958375A priority patent/EP1207868B1/de
Priority to PE2000000872A priority patent/PE20010530A1/es
Priority to PE2000000873A priority patent/PE20010531A1/es
Priority to ARP000104480A priority patent/AR025426A1/es
Priority to CO00064193A priority patent/CO5190687A1/es
Priority to CO00064190A priority patent/CO5190689A1/es
Priority to CZ2002673A priority patent/CZ2002673A3/cs
Priority to SK237-2002A priority patent/SK2372002A3/sk
Priority to HU0203204A priority patent/HUP0203204A3/hu
Priority to JP2001519881A priority patent/JP2003511351A/ja
Priority to PL00354362A priority patent/PL354362A1/xx
Priority to PE2000000883A priority patent/PE20010521A1/es
Priority to CN00815085A priority patent/CN1384735A/zh
Priority to MXPA02002189A priority patent/MXPA02002189A/es
Priority to BR0013826-6A priority patent/BR0013826A/pt
Priority to CA2391832A priority patent/CA2391832C/en
Priority to EP00964052A priority patent/EP1207858A1/de
Priority to ARP000104500A priority patent/AR025437A1/es
Priority to HK02108601.2A priority patent/HK1047232A1/zh
Priority to CO00064447A priority patent/CO5190691A1/es
Priority to KR1020027002783A priority patent/KR20020031421A/ko
Priority to AU75116/00A priority patent/AU782943B2/en
Priority to IL14842200A priority patent/IL148422A0/xx
Priority to PCT/EP2000/008402 priority patent/WO2001015667A1/de
Priority to NZ517683A priority patent/NZ517683A/en
Priority to UY26318A priority patent/UY26318A1/es
Priority to UY26320A priority patent/UY26320A1/es
Priority to UY26321A priority patent/UY26321A1/es
Publication of DE19940740A1 publication Critical patent/DE19940740A1/de
Priority to NO20020939A priority patent/NO20020939L/no
Priority to IL148406A priority patent/IL148406A/en
Priority to NO20020975A priority patent/NO20020975L/no
Priority to NO20020974A priority patent/NO329625B1/no
Priority to US10/084,248 priority patent/US6576260B2/en
Priority to US10/084,674 priority patent/US7572463B2/en
Priority to US10/084,682 priority patent/US6723343B2/en
Priority to ZA200202536A priority patent/ZA200202536B/xx
Priority to CY20071100802T priority patent/CY1107675T1/el
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE19940740A 1999-08-31 1999-08-31 Pharmazeutische Salze Withdrawn DE19940740A1 (de)

Priority Applications (83)

Application Number Priority Date Filing Date Title
DE19940740A DE19940740A1 (de) 1999-08-31 1999-08-31 Pharmazeutische Salze
IL14841100A IL148411A0 (en) 1999-08-31 2000-08-03 Delayed-action form of administration containing tramadol saccharinate
RU2002106741/15A RU2292877C2 (ru) 1999-08-31 2000-08-03 Лекарственная ретард-форма, содержащая сахаринат трамадола
HU0203623A HUP0203623A2 (hu) 1999-08-31 2000-08-03 Tramadol-szacharinátot tartalmazó, késleltetett hatású adagolási forma és alkalmazása
JP2001519896A JP2003508429A (ja) 1999-08-31 2000-08-03 医薬用トラマドール塩
JP2001519897A JP2003508430A (ja) 1999-08-31 2000-08-03 トラマドールサッカリナートを含有する徐放性投薬形
MXPA02002193A MXPA02002193A (es) 1999-08-31 2000-08-03 Forma de administracion de accion retardada que contiene sacarinato de tramadol.
HK02108598.7A HK1047229B (zh) 1999-08-31 2000-08-03 药物曲马朵盐
HK02108599.6A HK1047230B (zh) 1999-08-31 2000-08-03 含有曲马朵糖精酯的延迟作用给药形式
NZ517366A NZ517366A (en) 1999-08-31 2000-08-03 Pharmaceutical salts of tramadol and a sugar substitute
PCT/EP2000/007527 WO2001015683A1 (de) 1999-08-31 2000-08-03 Retardierte darreichungsform enthaltend tramadolsaccharinat
PL00354264A PL354264A1 (en) 1999-08-31 2000-08-03 Delayed-action form of administration containing tramadol saccharinate
AT00949447T ATE279186T1 (de) 1999-08-31 2000-08-03 Retardierte darreichungsform enthaltend tramadolsaccharinat
ES00958375T ES2284523T3 (es) 1999-08-31 2000-08-03 Sales farmaceuticas de tramadol.
DE2000508261 DE50008261D1 (de) 1999-08-31 2000-08-03 Retardierte darreichungsform enthaltend tramadolsaccharinat
BR0015048-7A BR0015048A (pt) 1999-08-31 2000-08-03 Sal farmacêutico, medicamento, uso de pelo menos um sal de tramadol e formas de apresentação
AT00958375T ATE359064T1 (de) 1999-08-31 2000-08-03 Pharmazeutische tramadolsalze
ES00949447T ES2226886T3 (es) 1999-08-31 2000-08-03 Forma de administracion de accion retardada que contiene sacarinato de tramadol.
IL14840600A IL148406A0 (en) 1999-08-31 2000-08-03 Pharmaceutical tramadol salts
CNB008150931A CN1202815C (zh) 1999-08-31 2000-08-03 含有曲马朵糖精盐的持续释放给药剂型
CA002388560A CA2388560A1 (en) 1999-08-31 2000-08-03 Sustained-release form of administration containing tramadol saccharinate
MXPA02002024A MXPA02002024A (es) 1999-08-31 2000-08-03 Sales farmaceuticas de tramadol.
BR0013825-8A BR0013825A (pt) 1999-08-31 2000-08-03 Formas de apresentação de tramadol
SK276-2002A SK2762002A3 (en) 1999-08-31 2000-08-03 Delayed-action form of administration containing tramadol saccharinate
SK235-2002A SK285987B6 (sk) 1999-08-31 2000-08-03 Farmaceutické soli tramadolu, liečivá obsahujúce tieto látky a ich použitie
KR1020027002625A KR20020031419A (ko) 1999-08-31 2000-08-03 트라마돌 사카리네이트를 함유하는 지효성 투여형
AU62798/00A AU781058B2 (en) 1999-08-31 2000-08-03 Delayed-action form of administration containing tramadol saccharinate
DK00958375T DK1207868T3 (da) 1999-08-31 2000-08-03 Farmaceutiske tramadolsalte
RU2002106748/15A RU2292876C2 (ru) 1999-08-31 2000-08-03 Фармацевтические соли трамадола
KR1020027002634A KR100730502B1 (ko) 1999-08-31 2000-08-03 약제학적 트라마돌 염 및 이를 함유하는 투여 제형
EP00949447A EP1207866B1 (de) 1999-08-31 2000-08-03 Retardierte darreichungsform enthaltend tramadolsaccharinat
CA002386690A CA2386690C (en) 1999-08-31 2000-08-03 Pharmaceutical tramadol salts
SI200030952T SI1207868T1 (sl) 1999-08-31 2000-08-03 Farmacevtske tramadolne soli
SI200030515T SI1207866T1 (en) 1999-08-31 2000-08-03 Delayed-action form of administration containing tramadol saccharinate
MYPI20003557A MY127683A (en) 1999-08-31 2000-08-03 Pharmaceutical tramadol salts
HU0302131A HUP0302131A2 (hu) 1999-08-31 2000-08-03 Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
PCT/EP2000/007526 WO2001015682A1 (de) 1999-08-31 2000-08-03 Pharmazeutische tramadolsalze
NZ517559A NZ517559A (en) 1999-08-31 2000-08-03 Sustained release pharmaceutical composition containing tramadol saccharinate
PT00958375T PT1207868E (pt) 1999-08-31 2000-08-03 Sais farmacêuticos de tramadol
CNB008121591A CN1200700C (zh) 1999-08-31 2000-08-03 药用曲马朵盐
PL354238A PL212105B1 (pl) 1999-08-31 2000-08-03 Farmaceutyczna sól tramadolu, środek leczniczy, zastosowanie soli tramadolu oraz postacie aplikacyjne
AU69921/00A AU781852B2 (en) 1999-08-31 2000-08-03 Pharmaceutical tramadol salts
DE50014244T DE50014244D1 (de) 1999-08-31 2000-08-03 Pharmazeutische tramadolsalze
CZ2002671A CZ2002671A3 (cs) 1999-08-31 2000-08-03 Léková forma se zpoľděným účinkem obsahující tramadolsacharinát
CZ20020674A CZ301259B6 (cs) 1999-08-31 2000-08-03 Farmaceutické soli tramadolu, léciva tyto látky obsahující a jejich použití
PT00949447T PT1207866E (pt) 1999-08-31 2000-08-03 Forma de administracao retardada contendo sacarinato de tramadol
EP00958375A EP1207868B1 (de) 1999-08-31 2000-08-03 Pharmazeutische tramadolsalze
PE2000000872A PE20010530A1 (es) 1999-08-31 2000-08-25 Formas de administracion de tramadol retardadas mediante un revestimiento que contiene la sustancia activa tramadol en forma de sacarinato de tramadol asi como eventualmente otros excipientes
PE2000000873A PE20010531A1 (es) 1999-08-31 2000-08-25 Sales farmaceuticas de la sustancia activa tramadol y al menos un edulcorante y formas de administracion que contienen estas sales
ARP000104480A AR025426A1 (es) 1999-08-31 2000-08-28 Sales farmaceuticas de la sustancia activa tramadol y al menos un edulcorante, medicamentos que contienen estas sales, el uso de estas sales para lapreparacion de medicamentos y formas de administracion que contienen esas sales
CO00064193A CO5190687A1 (es) 1999-08-31 2000-08-28 Formas de administracion de tramadol retardadas mediante un revestimiento que contiene la sustancia activa tramadol en forma de sacarinato de tramadol asi como eventualmente otros excipientes
CO00064190A CO5190689A1 (es) 1999-08-31 2000-08-28 Sales de tramadol formadas por tramadol y un edulcorante y formas farmaceuticas que contienen dichas sales
CZ2002673A CZ2002673A3 (cs) 1999-08-31 2000-08-29 Lékové formy pro orální podávání
SK237-2002A SK2372002A3 (en) 1999-08-31 2000-08-29 Oral dosage forms
HU0203204A HUP0203204A3 (en) 1999-08-31 2000-08-29 Oral dosage forms
JP2001519881A JP2003511351A (ja) 1999-08-31 2000-08-29 経口投薬形
PL00354362A PL354362A1 (en) 1999-08-31 2000-08-29 Oral dosage forms
PE2000000883A PE20010521A1 (es) 1999-08-31 2000-08-29 Formas de administracion oral con liberacion total controlada de sustancia activa, encontrandose una misma sustancia activa en forma de al menos dos sales distintas que en la forma de administracion se encuentran en estado solido y que presentan dife
CN00815085A CN1384735A (zh) 1999-08-31 2000-08-29 口服剂型
MXPA02002189A MXPA02002189A (es) 1999-08-31 2000-08-29 Formas de dosificacion oral.
BR0013826-6A BR0013826A (pt) 1999-08-31 2000-08-29 Formas orais de apresentação
CA2391832A CA2391832C (en) 1999-08-31 2000-08-29 Oral dosage forms
EP00964052A EP1207858A1 (de) 1999-08-31 2000-08-29 Orale darreichungsformen
ARP000104500A AR025437A1 (es) 1999-08-31 2000-08-29 Formas de administracion oral con liberacion total controlada de sustancia activa, encontrandose una misma sustancia activaen forma de al menos dos sales distintas que en la forma de administracion se encuentran en estado solido y que presentan diferente liberacionin vitro de la sustancia activa.
HK02108601.2A HK1047232A1 (zh) 1999-08-31 2000-08-29 口服剂型
CO00064447A CO5190691A1 (es) 1999-08-31 2000-08-29 Formas de administracion oral con la liberacion total controlada de sustancia activa, encontrandose una misma sustancia activa en forma de al menos dos sales distintas que en la forma de administracion se encuentran en estado solido y que presenta di
KR1020027002783A KR20020031421A (ko) 1999-08-31 2000-08-29 경구 투여 형태
AU75116/00A AU782943B2 (en) 1999-08-31 2000-08-29 Oral dosage forms
IL14842200A IL148422A0 (en) 1999-08-31 2000-08-29 Oral dosage forms
PCT/EP2000/008402 WO2001015667A1 (de) 1999-08-31 2000-08-29 Orale darreichungsformen
NZ517683A NZ517683A (en) 1999-08-31 2000-08-29 A controlled release oral dosage form containing at least two different salts of the active ingredient
UY26318A UY26318A1 (es) 1999-08-31 2000-08-31 Formas de administracion oral con liberacion total controlada de sustancia activa, encontrandose una misma sustancia activa en forma de al menos dos sales distintas que en la forma de administracion se encuentran en estado solido y que presentan dife
UY26320A UY26320A1 (es) 1999-08-31 2000-08-31 Sales farmaceuticas de la sustancia activa tramadol y al menos un edulcorante, medicamentos que contienen estas sales, el uso de estas sales para la preparacion de medicamentos y formas de administracion que contienen esas sales. ley 17164
UY26321A UY26321A1 (es) 1999-08-31 2000-08-31 Formas de administracion de tramadol retardadas mediante un revestimiento que contiene la sustancia activa tramadol en forma de sacarinato de tramadol asi como eventualmente otros excipientes
NO20020939A NO20020939L (no) 1999-08-31 2002-02-26 Oral administreringsform
IL148406A IL148406A (en) 1999-08-31 2002-02-27 Tramadol salts for pharmaceutical use
NO20020975A NO20020975L (no) 1999-08-31 2002-02-27 Retardierte administreringsformer inneholdende tramadolsakkarinat
NO20020974A NO329625B1 (no) 1999-08-31 2002-02-27 Farmasoytisk tramadolsalt, legemiddel inneholdende dette, administrasjonsform samt anvendelse av tramadolsaltet.
US10/084,248 US6576260B2 (en) 1999-08-31 2002-02-28 Sustained-release form of administration containing tramadol saccharinate
US10/084,674 US7572463B2 (en) 1999-08-31 2002-02-28 Oral dosage forms
US10/084,682 US6723343B2 (en) 1999-08-31 2002-02-28 Pharmaceutical tramadol salts
ZA200202536A ZA200202536B (en) 1999-08-31 2002-03-28 Pharmaceutical tramadol salts.
CY20071100802T CY1107675T1 (el) 1999-08-31 2007-06-18 Φαρμακευτικα αλατα τραμαδολης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19940740A DE19940740A1 (de) 1999-08-31 1999-08-31 Pharmazeutische Salze

Publications (1)

Publication Number Publication Date
DE19940740A1 true DE19940740A1 (de) 2001-03-01

Family

ID=7919846

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19940740A Withdrawn DE19940740A1 (de) 1999-08-31 1999-08-31 Pharmazeutische Salze
DE50014244T Expired - Lifetime DE50014244D1 (de) 1999-08-31 2000-08-03 Pharmazeutische tramadolsalze

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50014244T Expired - Lifetime DE50014244D1 (de) 1999-08-31 2000-08-03 Pharmazeutische tramadolsalze

Country Status (32)

Country Link
US (1) US6723343B2 (https=)
EP (1) EP1207868B1 (https=)
JP (1) JP2003508429A (https=)
KR (1) KR100730502B1 (https=)
CN (1) CN1200700C (https=)
AR (1) AR025426A1 (https=)
AT (1) ATE359064T1 (https=)
AU (1) AU781852B2 (https=)
BR (1) BR0015048A (https=)
CA (1) CA2386690C (https=)
CO (1) CO5190689A1 (https=)
CY (1) CY1107675T1 (https=)
CZ (1) CZ301259B6 (https=)
DE (2) DE19940740A1 (https=)
DK (1) DK1207868T3 (https=)
ES (1) ES2284523T3 (https=)
HK (1) HK1047229B (https=)
HU (1) HUP0302131A2 (https=)
IL (2) IL148406A0 (https=)
MX (1) MXPA02002024A (https=)
MY (1) MY127683A (https=)
NO (1) NO329625B1 (https=)
NZ (1) NZ517366A (https=)
PE (1) PE20010531A1 (https=)
PL (1) PL212105B1 (https=)
PT (1) PT1207868E (https=)
RU (1) RU2292876C2 (https=)
SI (1) SI1207868T1 (https=)
SK (1) SK285987B6 (https=)
UY (1) UY26320A1 (https=)
WO (1) WO2001015682A1 (https=)
ZA (1) ZA200202536B (https=)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066414A1 (de) * 2001-02-21 2002-08-29 Grünenthal GmbH Verfahren zur isolierung und reinigung von (1rs,2rs)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-cyclohexanol
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
WO2010004256A1 (en) * 2008-06-17 2010-01-14 E-Therapeutics Plc Controlled release treatment of depression
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US8114384B2 (en) 2004-07-01 2012-02-14 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US8114383B2 (en) 2003-08-06 2012-02-14 Gruenenthal Gmbh Abuse-proofed dosage form
US20120059066A1 (en) * 2001-02-28 2012-03-08 Grunenthal Gmbh Pharmaceutical salts
US8192722B2 (en) 2003-08-06 2012-06-05 Grunenthal Gmbh Abuse-proof dosage form
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
US8722086B2 (en) 2007-03-07 2014-05-13 Gruenenthal Gmbh Dosage form with impeded abuse
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
EP3009134A1 (en) * 2014-10-14 2016-04-20 Sapere IP, LLC A treatment method for primary premature ejaculation
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US10335373B2 (en) 2012-04-18 2019-07-02 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10449547B2 (en) 2013-11-26 2019-10-22 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US10695297B2 (en) 2011-07-29 2020-06-30 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10729658B2 (en) 2005-02-04 2020-08-04 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US11224576B2 (en) 2003-12-24 2022-01-18 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US11844865B2 (en) 2004-07-01 2023-12-19 Grünenthal GmbH Abuse-proofed oral dosage form

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
CA2476201C (en) * 2002-02-21 2009-09-01 Biovail Laboratories Incorporated Modified release formulations of at least one form of tramadol
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
CA2480826C (fr) * 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP4694207B2 (ja) * 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
NZ545202A (en) * 2003-08-06 2010-03-26 Gruenenthal Chemie Abuse-proofed dosage form comprising opiods and a high molecular weight polyethylene oxide
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
PT1765292T (pt) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US8221792B2 (en) 2005-07-07 2012-07-17 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
DK1940467T3 (da) 2005-09-09 2017-02-13 Paladin Labs Inc Lægemiddelsammensætning med langvarig frigivelse
CN101252932B (zh) 2005-09-09 2012-10-03 安吉利尼莱博法姆有限责任公司 用于一天给药一次的曲唑酮组合物
EP1785412A1 (en) * 2005-11-14 2007-05-16 IPCA Laboratories Limited Tramadol recovery process
GB0712101D0 (en) * 2007-06-22 2007-08-01 Therapeutics Ltd E Treatment of depression
CN101918418A (zh) * 2007-12-12 2010-12-15 阿尔迪默菲克斯技术有限责任公司 替诺福韦地索普西的固体形式
CN101467984B (zh) * 2007-12-25 2012-05-23 上海医药工业研究院 一种曲马多鼻用凝胶剂及其制备方法和用途
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
KR102793584B1 (ko) 2016-12-31 2025-04-09 바이오엑셀 테라퓨틱스 인코포레이티드 불안의 치료를 위한 설하 덱스메데토미딘의 용도
GR1009629B (el) 2018-02-20 2019-10-25 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Ποσιμα διαλυματα που περιλαμβανουν τραμαδολη
GR1009630B (el) 2018-03-14 2019-10-25 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Ποσιμα διαλυματα που περιλαμβανουν τραμαδολη και ακεταμινοφαινη
PL3813802T3 (pl) 2018-06-27 2025-04-22 Bioxcel Therapeutics, Inc. Formulacje błony zawierające deksmedetomidynę i sposoby ich wytwarzania
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. NON-SEDATIVE DEXMEDETOMIDINE-BASED TREATMENT REGIMEN
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054296A (en) * 1988-10-24 2000-04-25 Symbicom Ab 66 kDa antigen from Borrelia
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
NZ210386A (en) * 1983-12-09 1987-11-27 Sterling Drug Inc Saccharine salts and dentrifice compositions
CA1260941A (en) * 1983-12-09 1989-09-26 Sanofi Bis¬4-(substituted-amino)-1-pyridinium|alkane saccharin salts and process of preparation thereof
AU657351B2 (en) * 1991-09-06 1995-03-09 Mcneilab, Inc. Compositions comprising a tramadol material and any of codeine, oxycodone or hydrocodone and their use
US5837277A (en) * 1992-06-04 1998-11-17 Smithkline Beecham Corporation Palatable pharmaceutical compositions
US5330760A (en) * 1992-08-27 1994-07-19 Sterling Winthrop Inc. Effervescent antacid
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
US5919826A (en) * 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
EP1005861B1 (en) * 1997-04-11 2005-06-29 Nippon Shinyaku Co., Ltd. Remedies for frequent urination and urinary incontinence
ATE284211T1 (de) * 1997-11-06 2004-12-15 Lannacher Heilmittel Orale retard-präparation enthaltend tramadol sowie verfahren zu ihrer herstellung
CA2341522A1 (en) * 1998-08-27 2000-03-09 Bristol-Myers Squibb Company Novel pharmaceutical salt form
US6165512A (en) * 1998-10-30 2000-12-26 Fuisz Technologies Ltd. Dosage forms containing taste masked active agents
HUP0203198A3 (en) * 1999-08-20 2005-07-28 Ortho Mcneil Pharm Inc Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use
DE19940944B4 (de) * 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
AU781058B2 (en) * 1999-08-31 2005-05-05 Grunenthal Gmbh Delayed-action form of administration containing tramadol saccharinate
PE20020322A1 (es) * 2000-08-18 2002-05-10 Pharmacia Corp Formulacion oral de rapida disolucion de un inhibidor de la ciclooxigenasa 2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pharmazeutische Technologie 5.Aufl.1997, S.228 *

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6909017B2 (en) 2001-02-21 2005-06-21 Grunenthal Gmbh Method for isolating and purifying (1RS,2RS)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol
WO2002066414A1 (de) * 2001-02-21 2002-08-29 Grünenthal GmbH Verfahren zur isolierung und reinigung von (1rs,2rs)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-cyclohexanol
US20170137370A1 (en) * 2001-02-28 2017-05-18 Grünenthal GmbH Pharmaceutical salts
US10160719B2 (en) * 2001-02-28 2018-12-25 Grunenthal Gmbh Pharmaceutical salts
US20120059066A1 (en) * 2001-02-28 2012-03-08 Grunenthal Gmbh Pharmaceutical salts
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
WO2003099273A1 (en) * 2002-05-23 2003-12-04 Cilag Ag Adduct of topiramate and tramadol hydrochloride and uses thereof
US7378519B2 (en) 2002-05-23 2008-05-27 Cilag Gmbh International Adduct of topiramate and tramadol hydrochloride and uses thereof
US10369109B2 (en) 2002-06-17 2019-08-06 Grünenthal GmbH Abuse-proofed dosage form
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US9629807B2 (en) 2003-08-06 2017-04-25 Grünenthal GmbH Abuse-proofed dosage form
US8192722B2 (en) 2003-08-06 2012-06-05 Grunenthal Gmbh Abuse-proof dosage form
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US10130591B2 (en) 2003-08-06 2018-11-20 Grünenthal GmbH Abuse-proofed dosage form
US8420056B2 (en) 2003-08-06 2013-04-16 Grunenthal Gmbh Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US8114383B2 (en) 2003-08-06 2012-02-14 Gruenenthal Gmbh Abuse-proofed dosage form
US8309060B2 (en) 2003-08-06 2012-11-13 Grunenthal Gmbh Abuse-proofed dosage form
US11224576B2 (en) 2003-12-24 2022-01-18 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US8114384B2 (en) 2004-07-01 2012-02-14 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US11844865B2 (en) 2004-07-01 2023-12-19 Grünenthal GmbH Abuse-proofed oral dosage form
US8323889B2 (en) 2004-07-01 2012-12-04 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US10729658B2 (en) 2005-02-04 2020-08-04 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US8722086B2 (en) 2007-03-07 2014-05-13 Gruenenthal Gmbh Dosage form with impeded abuse
US9750701B2 (en) 2008-01-25 2017-09-05 Grünenthal GmbH Pharmaceutical dosage form
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
WO2010004256A1 (en) * 2008-06-17 2010-01-14 E-Therapeutics Plc Controlled release treatment of depression
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10493033B2 (en) 2009-07-22 2019-12-03 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US10695297B2 (en) 2011-07-29 2020-06-30 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10864164B2 (en) 2011-07-29 2020-12-15 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US10335373B2 (en) 2012-04-18 2019-07-02 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US10449547B2 (en) 2013-11-26 2019-10-22 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
EP3009134A1 (en) * 2014-10-14 2016-04-20 Sapere IP, LLC A treatment method for primary premature ejaculation
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations

Also Published As

Publication number Publication date
RU2292876C2 (ru) 2007-02-10
NO20020974L (no) 2002-02-27
EP1207868A1 (de) 2002-05-29
MY127683A (en) 2006-12-29
SK2352002A3 (en) 2002-07-02
HK1047229B (zh) 2007-11-23
AU6992100A (en) 2001-03-26
CA2386690C (en) 2009-02-10
DK1207868T3 (da) 2007-09-03
CY1107675T1 (el) 2013-04-18
HUP0302131A2 (hu) 2003-12-29
CO5190689A1 (es) 2002-08-29
EP1207868B1 (de) 2007-04-11
NZ517366A (en) 2004-07-30
JP2003508429A (ja) 2003-03-04
CN1371277A (zh) 2002-09-25
NO329625B1 (no) 2010-11-22
ZA200202536B (en) 2003-09-23
BR0015048A (pt) 2003-04-29
SK285987B6 (sk) 2008-01-07
CN1200700C (zh) 2005-05-11
DE50014244D1 (de) 2007-05-24
ES2284523T3 (es) 2007-11-16
SI1207868T1 (sl) 2007-08-31
AU781852B2 (en) 2005-06-16
ATE359064T1 (de) 2007-05-15
RU2002106748A (ru) 2004-01-10
UY26320A1 (es) 2000-10-31
CZ2002674A3 (cs) 2002-05-15
NO20020974D0 (no) 2002-02-27
WO2001015682A1 (de) 2001-03-08
CZ301259B6 (cs) 2009-12-23
AR025426A1 (es) 2002-11-27
IL148406A0 (en) 2002-09-12
PE20010531A1 (es) 2001-06-16
US20030158242A1 (en) 2003-08-21
KR20020025240A (ko) 2002-04-03
CA2386690A1 (en) 2001-03-08
US6723343B2 (en) 2004-04-20
HK1047229A1 (en) 2003-02-14
PL212105B1 (pl) 2012-08-31
IL148406A (en) 2007-06-03
MXPA02002024A (es) 2002-08-20
PL354238A1 (en) 2003-12-29
PT1207868E (pt) 2007-05-31
KR100730502B1 (ko) 2007-06-22

Similar Documents

Publication Publication Date Title
EP1207868B1 (de) Pharmazeutische tramadolsalze
EP1390023B1 (de) Pharmazeutische salze von 1-phenyl-3-dimethylamino-propan-verbindungen
DE69802543T2 (de) Verbesserte multipartikel-tablette mit schnellauflösbarkeit
AT409083B (de) Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
DE2903269A1 (de) Metronidazolphosphorsaeure(salze), ihre herstellung und verwendung sowie diese enthaltende arzneimittel
EP0250648B1 (de) Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen
DE69824313T2 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
DE3726945A1 (de) L-carnitinderivate der valproinsaeure und diese enthaltende arzneimittel
DE3034975C2 (de) Arzneimittelkombination zur Behandlung infektiöser Atemwegerkrankungen
EP1469835A2 (de) Stabile salze von o-acetylsalicyls ure mit basischen a minos uren ii
EP0471388A2 (de) Mittel zur Behandlung der Herzinsuffizienz
EP3235492B1 (de) Verwendung von homoeriodictyol (hed) zum reduzieren der magensäuresekretions-stimulierenden wirkung von n-acetyl-4-aminophenol (paracetamol)
DE2532180C2 (de) Verwendung von Etozolin bei der Bekämpfung der Hypertonie
DE2749213C2 (https=)
EP0418553A1 (de) Hochwirksame, schnell resorbierbare Zubereitungsformen von Glibenclamid, Verfahren zu ihrer Herstellung und ihre Verwendung
DE3511236A1 (de) Praeparat mit synergistischer bronchienerweiternder wirkung und verfahren zu dessen herstellung
DE2004177A1 (de) Neue Glutaminsaeurederivate
DD232488A5 (de) Verfahren zur herstellung von phenoxypropanolaminsalzen
DE10250566A1 (de) Pharmazeutische Zusammensetzung, enthaltend Oxcarbazepin mit verzögerter Wirkstofffreisetzung

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8125 Change of the main classification

Ipc: C07C217/74

8130 Withdrawal